Latest news with #NatcoPharma
The Hindu
6 days ago
- Business
- The Hindu
Natco Pharma's Hyderabad API plant receives EIR from U.S. FDA
Generic drugmaker Natco Pharma has received an establishment inspection report from the U.S. Food and Drug Administration for its active pharmaceutical ingredient manufacturing facility in Hyderabad. The U.S. FDA had inspected the API facility, in Mekaguda here, from June 9-13 and issued Form 483 with one observation. The regulator had classified it as 'voluntary action indicated' (VAI), the company said on Thursday, announcing issue of the EIR. Natco Pharma shares closed 3.58% lower at ₹997.70 each on the BSE.
Business Standard
6 days ago
- Business
- Business Standard
Natco Pharma receives USFDA EIR for Hyderabad API facility
Natco Pharma informed that the U.S. Food and Drug Administration (US FDA) has issued an EIR for its active pharmaceutical ingredient (API) division located in Mekaguda, Hyderabad, Telangana. The US FDA had conducted an inspection at the companys aforementioned unit from 9 June to 13 June 2025. Post the inspection, the company received one observation in Form-483, which was classified as voluntary action indicated (VAI). In a regulatory filing made during market hours today, Natco Pharma announced that it has received an establishment inspection report (EIR) for its API facility located in Mekaguda. NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The companys consolidated net profit increased 5.3% to Rs 406.60 crore on a 14.3% jump in revenue from operations to Rs 1,221 crore in Q4 FY25 over Q4 FY24. Shares of Natco Pharma slipped 3% to Rs 1,003.75 on the BSE.
Time of India
6 days ago
- Business
- Time of India
Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa's Adcock Ingram
Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday's trade after the company announced its plan to acquire a 35.75% stake in South Africa-based Adcock Ingram Holdings (AIHL) for $226 million (approximately Rs 2,000 crore). The proposed all-cash deal involves acquiring nearly 36% of AIHL from minority shareholders. Natco said the strategic investment aims to expand its geographical footprint in South Africa , marking a significant step toward diversifying beyond its key markets. Founded in 1890, Adcock Ingram operates across four segments—prescription, consumer health, over-the-counter (OTC), and hospital products—with a wide portfolio of branded and generic formulations, critical-care products, and consumer healthcare offerings. The acquisition is expected to be completed in 2025. Following the deal, Adcock will continue as a private South African entity, with Bidvest retaining 64.25% and Natco holding 35.75%, including its existing 0.80% stake. Post-transaction, Natco will consolidate its share of AIHL's net profits, which stood at $45 million for the year ended June 2024, on total revenue of $536 million. 'Adcock Ingram is a respected pharmaceutical company with well-recognised brands and a leading position in South Africa. This acquisition gives Natco an established entry into the Southern African market, opens new revenue streams, and strengthens our footprint in a key emerging region,' said Rajeev Nannapaneni, CEO and Vice-Chairman of Natco Pharma. Live Events In addition to the acquisition, Natco's board approved the incorporation of a wholly owned subsidiary in South Africa with an investment of up to Rs 2,100 crore this year. The move is part of the company's strategy to enter new geographies for sustained growth and improved profitability. The board also approved a proposal to liquidate its wholly owned subsidiary Time Cap Overseas (TCOL) and directly hold the investment in step-down subsidiary NatcoFarma do Brasil. Brokerage View Brokerage firm Nuvama raised its target price on Natco Pharma to Rs 1,110 from Rs 990, while maintaining a 'Hold' rating. It believes the Adcock deal strengthens Natco's presence in emerging markets, supports diversification beyond the US, and improves R&D leverage. The deal is expected to be 7–9% EPS accretive, driven by prescription revenue synergies. Also read: The great Adani bet: Mutual funds & LIC are buying what GQG, FIIs are selling Nuvama also noted that with Rs 15 billion in post-deal cash, Natco may pursue further M&A opportunities to fuel long-term growth. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Time of India
7 days ago
- Business
- Time of India
Natco Pharma to buy over 35% in South Africa's Adcock Ingram
Natco Pharma, based in Hyderabad, is set to acquire a 35.75% stake in Adcock Ingram, South Africa's second-largest drugmaker, for ₹2,000 crore. This all-cash deal provides Natco Pharma with a strong entry into high-growth African markets and expands its product offerings. The acquisition, expected to finalize in four months, aligns with Natco's strategy to grow in emerging markets. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Hyderabad-based Natco Pharma on Wednesday said it has agreed to buy a 35.75% stake in Adcock Ingram , South Africa's second-largest drugmaker, for '2,000 all-cash deal will give Natco Pharma a foothold in some high-growth African markets besides an opportunity to expand its product Nannapaneni, chief executive officer and vice chairman of Natco Pharma, told ET that the Adcock deal is aligned with the company's plan of expanding its presence in emerging markets . "Besides, this was within our valuation range," he said the company reserves the right of first refusal in case the shareholders of Adcock Ingram plan to divest additional equity stake. The Bidwest group holds 64.25% stake in the company."Adcock Ingram will be delisted from the JSE (Johannesburg Stock Exchange) if the transaction proceeds," Natco Pharma said in a statement, adding that the estimated transaction completion time is four months, assuming that there are no regulatory told investors over a call that the deal is a significant step as it would have taken Natco Pharma decades to build business in Africa on its Ingram has a presence across segments-prescription, OTC ( over-the-counter drugs ), consumer products and the hospitals the first half of FY25, Adcock Ingram recorded sales of $262 million. In FY24, its sales stood at $536 million and EBITDA at $78 million. It had a gross margin of 33.4% in EV/EBITDA for the Natco deal is 7.83, according to an investor presentation by Natco Pharma said it can potentially bring significant value through its research and development programmes, dossier approvals, intellectual property sharing, experience in regulated market operations, sourcing and global marketing for the new markets in Africa and regulated markets in the the investor call, Nannapaneni hinted at another deal under examination but refused to share any details. For FY25, Natco Pharma recorded sales of '4,784 crore and a profit after tax of '1,883 crore. The company had a cash reserve of '3,000 crore, of which '2,000 crore will be used for the Adcock deal.
Economic Times
7 days ago
- Business
- Economic Times
Natco Pharma to buy over 35% in South Africa's Adcock Ingram
Synopsis Natco Pharma, based in Hyderabad, is set to acquire a 35.75% stake in Adcock Ingram, South Africa's second-largest drugmaker, for ₹2,000 crore. This all-cash deal provides Natco Pharma with a strong entry into high-growth African markets and expands its product offerings. The acquisition, expected to finalize in four months, aligns with Natco's strategy to grow in emerging markets. Representative image. Mumbai: Hyderabad-based Natco Pharma on Wednesday said it has agreed to buy a 35.75% stake in Adcock Ingram, South Africa's second-largest drugmaker, for '2,000 crore. The all-cash deal will give Natco Pharma a foothold in some high-growth African markets besides an opportunity to expand its product portfolio. Rajeev Nannapaneni, chief executive officer and vice chairman of Natco Pharma, told ET that the Adcock deal is aligned with the company's plan of expanding its presence in emerging markets. "Besides, this was within our valuation range," he said the company reserves the right of first refusal in case the shareholders of Adcock Ingram plan to divest additional equity stake. The Bidwest group holds 64.25% stake in the company. "Adcock Ingram will be delisted from the JSE (Johannesburg Stock Exchange) if the transaction proceeds," Natco Pharma said in a statement, adding that the estimated transaction completion time is four months, assuming that there are no regulatory delays. Nannapaneni told investors over a call that the deal is a significant step as it would have taken Natco Pharma decades to build business in Africa on its own. Adcock Ingram has a presence across segments-prescription, OTC (over-the-counter drugs), consumer products and the hospitals business. For the first half of FY25, Adcock Ingram recorded sales of $262 million. In FY24, its sales stood at $536 million and EBITDA at $78 million. It had a gross margin of 33.4% in EV/EBITDA for the Natco deal is 7.83, according to an investor presentation by Natco Pharma said it can potentially bring significant value through its research and development programmes, dossier approvals, intellectual property sharing, experience in regulated market operations, sourcing and global marketing for the new markets in Africa and regulated markets in the the investor call, Nannapaneni hinted at another deal under examination but refused to share any details. For FY25, Natco Pharma recorded sales of '4,784 crore and a profit after tax of '1,883 crore. The company had a cash reserve of '3,000 crore, of which '2,000 crore will be used for the Adcock deal.
